Jeanmarie Guenot Ph.D.
Founder, President & CEO
Jeanmarie Guenot, Ph.D. has over 25 years of experience in the pharmaceutical and biotechnology industries. She has worked at both public and private companies, and across research and development, corporate development and venture capital. Among her achievements are several noteworthy bio-pharma mergers/acquisitions and licensing deals. Her experience spans small molecules and proteins and a variety of therapeutic areas including inflammation, autoimmune disease, oncology, cardiology, metabolic diseases, ophthalmology and neurology. She has more recently focused in immuno-oncology and specifically, in T cell engagement and bi-specific antibody drug development. Since 2013, Dr. Guenot has been the President & CEO of Amphivena Therapeutics, Inc., a clinical stage company developing a novel CD33/CD3 bispecific antibody therapeutic for cancer. She also co-founded Harpoon Therapeutics in 2015 and was its founding CEO and President. She co-founded Maverick Therapeutics in 2016, a spinout of Harpoon, and executed a build-to-buy deal with Takeda in January 2017 which comprised $125 million in funding including R&D support, option fee and equity investment.
Prior to her current role, Dr. Guenot co-founded, built and ran SKS Ocular, a start-up ophthalmic company incubator, focused on dry AMD, sustained release ocular drug delivery technologies and therapeutics for glaucoma, macular degeneration and ocular inflammation. She was a business advisor for Hoffmann-La Roche in Basel and Shanghai, and she was Vice President of Corporate & Business Development at PDL BioPharma, where she led licensing, mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios. She led and negotiated the Biogen Idec-PDL 50:50 co-development and co-commercialization strategic collaboration, which involved three Phase 2 cancer and autoimmune disease drug candidates. This $800 M transaction included a $100 M equity investment in PDL and a therapeutic candidate with indications split between Biogen Idec/PDL and Hoffmann-La Roche. She also licensed the ophthalmic indication for the oncology drug to Ophthotech. She has portfolio, project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases, neurology and ophthalmic diseases.
Dr. Guenot started her business career at Atlas Venture, where she managed venture capital investments and built life science companies. She started her scientific career as a principal scientist in Preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic diseases, inflammation, autoimmune diseases and oncology. Dr. Guenot trained in physical and medicinal chemistry, with a focus in quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. She earned her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.